Literature DB >> 1968762

Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis.

Y Kuwazuru1, A Yoshimura, S Hanada, M Ichikawa, T Saito, K Uozumi, A Utsunomiya, T Arima, S Akiyama.   

Abstract

The overexpression of a cell-surface glycoprotein termed P-glycoprotein (P-gp) is frequently associated with multidrug resistance (MDR) in cell lines in vitro. To evaluate the implications of P-gp expression in clinical drug-resistance, we examined the expression of P-gp in fresh leukaemia cells from chronic myelogenous leukaemia (CML) patients in blast crisis. By using immunoblotting with a monoclonal antibody against P-gp, C219, we showed that leukaemia cells from three CML patients in blast crisis were P-gp negative at the stage when these patients were in complete remission, and that the cells showed high levels of P-gp expression at times when the same patients had relapsed and had not responded to chemotherapy. Six out of 11 patients (nine in the refractory state) were P-gp positive and they rarely responded to chemotherapy. These data suggest that the expression of P-gp is closely associated with drug-resistance in CML.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968762     DOI: 10.1111/j.1365-2141.1990.tb02533.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

1.  Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy.

Authors:  Brian J Dewar; Kayvan Keshari; Rex Jeffries; Petras Dzeja; Lee M Graves; Jeffrey M Macdonald
Journal:  Metabolomics       Date:  2010-03-23       Impact factor: 4.290

Review 2.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 3.  P-glycoprotein, multidrug resistance and tumor progression.

Authors:  G Bradley; V Ling
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 4.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

5.  Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.

Authors:  V Nüssler; R Pelka-Fleischer; H Zwierzina; C Nerl; B Beckert; E Gullis; F Gieseler; S Bock; R Bartl; P E Petrides
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

6.  Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells.

Authors:  Xing-Xiang Peng; Zhi Shi; Amit K Tiwari; Vijaya L Damaraju; Liwu Fu; Carol E Cass; Charles R Ashby; Gary D Kruh; Zhe-Sheng Chen
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

7.  PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia.

Authors:  C F Rochlitz; E de Kant; A Neubauer; I Heide; R Böhmer; J Oertel; D Huhn; R Herrmann
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

8.  P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine A containing protocols.

Authors:  M Beksaç; H Akan; H Koç; O Ilhan; S Ertürk; A Güneyli; Y Ikizünal; O S Sardaş
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 9.  Is there a cloud in the silver lining for imatinib?

Authors:  S C Paterson; K D Smith; T L Holyoake; H G Jørgensen
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

10.  The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.

Authors:  Gabriela Nestal de Moraes; Paloma Silva Souza; Fernanda Casal de Faria Costas; Flavia Cunha Vasconcelos; Flaviana Ruade Souza Reis; Raquel Ciuvalschi Maia
Journal:  Leuk Res Treatment       Date:  2012-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.